199 related articles for article (PubMed ID: 34069498)
1.
Díaz M; Lobo F; Hernández D; Amesty Á; Valdés-Baizabal C; Canerina-Amaro A; Mesa-Herrera F; Soler K; Boto A; Marín R; Estévez-Braun A; Lahoz F
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069498
[TBL] [Abstract][Full Text] [Related]
2. Unique SERM-like properties of the novel fluorescent tamoxifen derivative FLTX1.
Marrero-Alonso J; Morales A; García Marrero B; Boto A; Marín R; Cury D; Gómez T; Fernández-Pérez L; Lahoz F; Díaz M
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):898-910. PubMed ID: 23727370
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
[TBL] [Abstract][Full Text] [Related]
4. Antiestrogens--tamoxifen, SERMs and beyond.
Dhingra K
Invest New Drugs; 1999; 17(3):285-311. PubMed ID: 10665480
[TBL] [Abstract][Full Text] [Related]
5. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
6. Progress in the prevention of breast cancer: concept to reality.
Jordan VC
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):269-77. PubMed ID: 11162935
[TBL] [Abstract][Full Text] [Related]
7. A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer.
Rasmussen LM; Zaveri NT; Stenvang J; Peters RH; Lykkesfeldt AE
Breast Cancer Res Treat; 2007 Dec; 106(2):191-203. PubMed ID: 17268816
[TBL] [Abstract][Full Text] [Related]
8. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
Reiter R; Oh AS; Wellstein A; Riegel AT
Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
[TBL] [Abstract][Full Text] [Related]
9. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.
Park WC; Jordan VC
Trends Mol Med; 2002 Feb; 8(2):82-8. PubMed ID: 11815274
[TBL] [Abstract][Full Text] [Related]
10. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen to raloxifene and beyond.
O'Regan RM; Jordan VC
Semin Oncol; 2001 Jun; 28(3):260-73. PubMed ID: 11402436
[TBL] [Abstract][Full Text] [Related]
12. Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.
Bianco NR; Perry G; Smith MA; Templeton DJ; Montano MM
Mol Endocrinol; 2003 Jul; 17(7):1344-55. PubMed ID: 12714703
[TBL] [Abstract][Full Text] [Related]
13. Colocalization of Estrogen Receptors with the Fluorescent Tamoxifen Derivative, FLTX1, Analyzed by Confocal Microscopy.
Morales A; Marín R; Marrero-Alonso J; Boto A; Díaz M
Methods Mol Biol; 2016; 1366():163-173. PubMed ID: 26585134
[TBL] [Abstract][Full Text] [Related]
14. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
Johnston SR
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
[TBL] [Abstract][Full Text] [Related]
15. Current status of selective estrogen receptor modulators (SERMs).
Conzen SD
Cancer J; 2003; 9(1):4-14. PubMed ID: 12602762
[No Abstract] [Full Text] [Related]
16. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
17. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
[TBL] [Abstract][Full Text] [Related]
19. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.
Namba R; Young LJ; Maglione JE; McGoldrick ET; Liu S; Wurz GT; DeGregorio MW; Borowsky AD; MacLeod CL; Cardiff RD; Gregg JP
Breast Cancer Res; 2005; 7(6):R881-9. PubMed ID: 16280035
[TBL] [Abstract][Full Text] [Related]
20. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance.
Sengupta S; Jordan VC
Adv Exp Med Biol; 2008; 630():206-19. PubMed ID: 18637493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
